Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
2006 Standout
Twist Transcriptionally Up-regulates AKT2 in Breast Cancer Cells Leading to Increased Migration, Invasion, and Resistance to Paclitaxel
2007
Akt1 Ablation Inhibits, whereas Akt2 Ablation Accelerates, the Development of Mammary Adenocarcinomas in Mouse Mammary Tumor Virus (MMTV)-ErbB2/Neu and MMTV-Polyoma Middle T Transgenic Mice
2007
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects
2005
Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her‐2/neu antigen
2002
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
2000
Untangling the ErbB signalling network
2001 Standout
Neu and its ligands: From an oncogene to neural factors
1993
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
1996
MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo
1995
In silico prediction of protein-protein interactions in human macrophages
2014 Standout
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016
Epidermal growth factor-related peptides in the pathogenesis of human breast cancer
1994
Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency
1998
Signal transduction by the neu/ebrB-2 receptor: A potential target for anti-tumor therapy
1992
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
1994
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
1999
HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
1997
c-erb B2 amplification and overexpression in human tumors
1991
The biology of erbB-2/nue/HER-2 and its role in cancer
1994
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
2005
Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
1992
EGFR Antagonists in Cancer Treatment
2008 Standout
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking
1999
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Oncogenic kinase signalling
2001 StandoutNature
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 Standout
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
1999 Standout
The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*
1992
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands
1998
Cyclin E and Survival in Patients with Breast Cancer
2002
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
2005
Naturally occurring B-cell responses to breast cancer
2003
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
1996 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Autocrine Signalling Through erbB Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines
2003
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Epidermal Growth Factor (EGF) Receptor-dependent ERK Activation by G Protein-coupled Receptors
2001 StandoutNobel
In vivo cancer targeting and imaging with semiconductor quantum dots
2004 Standout
Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells
2004 StandoutNobel
The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression
2005
Upstream and downstream of mTOR
2004 Standout
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
PI3K/Akt and apoptosis: size matters
2003
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
2007 StandoutNature
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Perturbations of the AKT signaling pathway in human cancer
2005
AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression
2004
The microenvironment of the tumour–host interface
2001 StandoutNature
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
1996 Standout
Biological Characteristics of Micrometastatic Cancer Cells in Bone Marrow
1999
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
The type 1 (EGFR-related) family of growth factor receptors and their ligands
1992
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes
1998
PI3K/Akt signalling pathway and cancer
2003 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
4. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer
1990
p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
1999
AKT/PKB Signaling: Navigating the Network
2017 Standout
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
1997
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1
1999 StandoutNobel
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis: Figure 1
2004
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
1992
c-erbB-4 protein expression in human breast cancer
2000
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
2008 Standout
p53-Mediated Regulation of Proliferating Cell Nuclear Antigen Expression in Cells Exposed to Ionizing Radiation
1999
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.
1999
Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.
1995
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland.
1995
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
Identification of Novel Saccharomyces cerevisiaeProteins with Nuclear Export Activity: Cell Cycle-Regulated Transcription Factor Ace2p Shows Cell Cycle-Independent Nucleocytoplasmic Shuttling
2000 StandoutNobel
Degradation of the Met Tyrosine Kinase Receptor by the Ubiquitin-Proteasome Pathway
1997 StandoutNobel
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.
1993
Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells.
1994
Role of HER2 gene overexpression in breast carcinoma
2000
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2002 Standout
Significance analysis of microarrays applied to the ionizing radiation response
2001 Standout
The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis.
1998
Tyrosine Kinase Inhibition: An Approach to Drug Development
1995 Science
BRCA1 and BRCA2 hereditary breast carcinoma phenotypes
1997
c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination
2001 StandoutNobel
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
Spectral Imaging and Pathology: Seeing More
2004
Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.
1993
Works of D Chin being referenced
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.
1996
Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
1993
A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.
1992
Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior.
1994
Differentiation of cultured human breast cancer cells (AU‐565 and MCF‐7) associated with loss of cell surface HER‐2/neu antigen
1990
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
1992
The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins
2004
HER-2/neu oncogene expression and proliferation in breast cancers.
1990
Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
1996
Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
1991
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival
2002
HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein
1995
Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers.
1997
Prostate Adenocarcinoma: An Image Analysis Technique for DNA Ploidy Determination
1993
Biological grading of breast cancer using antibodies to proliferating cells and other markers.
1989
Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus.
1997